These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26692394)

  • 1. Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review.
    Okonkwo RI; Weidmann AE; Effa EE
    Drug Saf; 2016 Mar; 39(3):209-18. PubMed ID: 26692394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
    Nkhoma ET; Rosenblatt L; Myers J; Villasis-Keever A; Coumbis J
    PLoS One; 2016; 11(12):e0166982. PubMed ID: 27941989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
    Cooper RD; Wiebe N; Smith N; Keiser P; Naicker S; Tonelli M
    Clin Infect Dis; 2010 Sep; 51(5):496-505. PubMed ID: 20673002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
    Bedimo R; Rosenblatt L; Myers J
    HIV Clin Trials; 2016 Nov; 17(6):246-266. PubMed ID: 27809711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
    Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
    HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Epi-TAF for Tenofovir Disoproxil Fumarate?
    Walensky RP; Horn TH; Paltiel AD
    Clin Infect Dis; 2016 Apr; 62(7):915-8. PubMed ID: 26658300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
    Decloedt EH; Lesosky M; Maartens G; Joska JA
    AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
    Angione SA; Cherian SM; Özdener AE
    J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir and bone health.
    Grant PM; Cotter AG
    Curr Opin HIV AIDS; 2016 May; 11(3):326-32. PubMed ID: 26859637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
    Mugwanya KK; Baeten JM
    Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir-associated kidney disease in Africans: a systematic review.
    Mtisi TJ; Ndhlovu CE; Maponga CC; Morse GD
    AIDS Res Ther; 2019 Jun; 16(1):12. PubMed ID: 31171021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
    Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
    J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
    Mofenson LM; Baggaley RC; Mameletzis I
    AIDS; 2017 Jan; 31(2):213-232. PubMed ID: 27831952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.
    Hemkens LG; Ewald H; Santini-Oliveira M; Bühler JE; Vuichard D; Schandelmaier S; Stöckle M; Briel M; Bucher HC
    HIV Clin Trials; 2015 Oct; 16(5):178-89. PubMed ID: 26395328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoporosis-Related Fractures in HIV-Infected Patients Receiving Long-Term Tenofovir Disoproxil Fumarate: An Observational Cohort Study.
    Komatsu A; Ikeda A; Kikuchi A; Minami C; Tan M; Matsushita S
    Drug Saf; 2018 Sep; 41(9):843-848. PubMed ID: 29623648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.
    Jotwani V; Scherzer R; Estrella MM; Jacobson LP; Witt MD; Palella FJ; Macatangay B; Bennett M; Parikh CR; Ix JH; Shlipak MG
    Am J Kidney Dis; 2016 Oct; 68(4):571-581. PubMed ID: 27287300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis.
    Ewald H; Santini-Oliveira M; Bühler JE; Vuichard D; Schandelmaier S; Stöckle M; Briel M; Bucher HC; Hemkens LG
    HIV Clin Trials; 2017 Jan; 18(1):17-27. PubMed ID: 27951755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
    Grant PM; Kitch D; McComsey GA; Tierney C; Ha B; Brown TT
    HIV Clin Trials; 2015; 16(2):66-71. PubMed ID: 25872972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.
    Casado JL; Bañón S; Santiuste C; Serna J; Guzman P; Tenorio M; Liaño F; del Rey JM
    AIDS; 2016 Jan; 30(2):231-9. PubMed ID: 26684820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.